CCR9 Antibody (242503) [Janelia Fluor® 669]
Novus Biologicals, part of Bio-Techne | Catalog # FAB2160JF669
Conjugate
Catalog #
Key Product Details
Species Reactivity
Mouse
Applications
CyTOF-ready, Flow Cytometry
Label
Janelia Fluor 669
Antibody Source
Monoclonal Rat IgG2B Clone # 242503
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Y3 rat myeloid cell line transfected with mouse CCR9
Met1-Leu369
Accession # Q9WUT7
Met1-Leu369
Accession # Q9WUT7
Specificity
Detects mouse CCR9 in flow cytometry. Stains mouse CCR9-transfected cells but not irrelevant transfectants.
Clonality
Monoclonal
Host
Rat
Isotype
IgG2B
Applications for CCR9 Antibody (242503) [Janelia Fluor® 669]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CCR9
Alternate Names
CCR9, CD199, CDw199
Gene Symbol
CCR9
Additional CCR9 Products
Product Documents for CCR9 Antibody (242503) [Janelia Fluor® 669]
Product Specific Notices for CCR9 Antibody (242503) [Janelia Fluor® 669]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...